SUMMARY We characterized the hemodynamk and endocrine changes associated with the evolution of steroid-induced hypertension in conscious, trained, instrumented dogs given intramuscular injections of deoxycorticosterone (DOC) pivalate on Days 1 (20 mg/kg) and 14 (10 mg/kg) of the study. Because hypertension could be produced in these dogs without salt loading and unilateral nephrectomy, the research afforded a novel opportunity to determine the primary effects of DOC excess on the renin-angiotensin and sympathetic nervous systems, and on vasopressin levels. Both before and during 28 days of DOC treatment, regular measurements of mean arterial pressure, heart rate, cardiac output, and total peripheral resistance were coupled with serial determinations of plasma and cerebrospinal fluid levels of angiotensin II, vasopressin, norepinephrine, and electrolytes. DOC induced a progressive rise in mean arterial pressure associated with increased cardiac output and no change in heart rate. These hemodynaqiic changes were accompanied by sustained decreases in plasma renin activity, and in plasma, but not cerebrospinal fluid, angiotensin II. In contrast, plasma and cerebrospinal fluid vasopressin rose transiently on the 7th and 14th days of the study, respectively. After anesthesia with morphine and chloralose, the hemodynamic response to occlusion of a sole innervated carotid artery was evaluated on the 5th week before and after cervical vagotomy. Compared to normal unimals, dogs with DOC-induced hypertension showed a reduced pressor response to carotid occlusion associated with suppression of reflex tachycardia; vagotomy partially restored the pressor response to normal levels. The data suggest that DOC-induced hypertension changes central hormonal influences of cardiovascular function, and also alters cardiopulmonary baroreceptor reflex control of peripheral sympathetic nerve activity. of the renin-angiotensin system (RAS) and sympathetic control mechanisms, 1 a physiological understanding of the relative importance of these systems to the pathogenesis of steroid-induced hypertension remains to be established.
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A recent report 2 suggested that repeated injections of deoxycorticosterone (DOC) cause sustained hypertension in dogs without the additional salt-retaining procedures of unilateral nephrectomy or salt feeding. The obvious value of this technique prompted us to define in conscious, trained dogs the long-term hemodynamic, humoral, and neurohormonal effects of DOC. We also examined features of the baroreceptor reflex component by determining in these animals the potency of the carotid occlusion reflex (COR) before and after removal of the cardiopulmonary receptors.
Materials and Methods
Sixteen male, mongrel dogs (body weight, 17-22 kg) were instrumented with electromagnetic flow NEUROHORMONAL MECHANISMS OF DOC-INDUCED HYPERTENSION/t/eno et al.
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probes (Micron Instruments, Los Angeles, CA, USA) around the ascending aorta and with catheters into an iliac artery. 3 They were fed a diet (Purina dog chow, Fetzer Brothers, Bedford, OH, USA) containing 65 mEq of sodium and 70 mEq of potassium per day. Water was given ad libitum. Three weeks later, 11 dogs received intramuscular (i.m.) injections of DOC pivalate (Percorten pivalate, CIBA, Summit, NJ, USA) on Days 1 (20 mg/kg) and 14 (10 mg/kg) of the experiment. Five other dogs were injected with the vehicle only.
The aortic blood flow and arterial pressure of 13 of the 16 conscious dogs were recorded at regular intervals during the week before and the 4 weeks after the first injection of either DOC or vehicle. The mean values of mean arterial pressure (MAP), heart rate, cardiac output, and total peripheral resistance (TPR) were determined from beat-by-beat measurements of each variable taken during 1-hour recording sessions and processed with a digital computer. 3 During recording sessions, arterial blood (10 ml) was collected for the assay of the concentrations of norepinephrine, epinephrine, plasma renin activity (PRA), angiotensinogen, immunoreactive angiotensin II (irAng II) and arginine vasopressin (AVP) in plasma. The techniques for these assays, identity of angiotensin products, and canine normal values are documented. 4 -5 Cerebrospinal fluid (3 ml) was also removed once during the control period and twice during the experimental period by puncturing the cisterna magna with a 20-gauge needle after dogs were lightly anesthetized with sodium thiamylal (Surital, Parke-Davis, Morris Plains, NJ, USA), 10 mg/kg i.v.
The hemodynamic response to occlusion of a sole innervated carotid artery was determined in the 5th week of the study in dogs anesthetized with a combination of morphine (2 mg/kg i.m.) and chloralose (65 mg/kg i.v.). Details of the surgical procedure to effect partial baroreceptor denervation (removal of the carotid sinus and vagus nerve on the right side, and section of the left aortic depressor nerve) and hemodynamic attributes of the COR are published elsewhere. 6 ' 7 In addition, the pressures in the right atrium and the carotid sinus were measured through catheters inserted into a jugular vein and a lingual artery, respectively.
All data are shown as mean ± 1 SE. Statistical analysis was done using one-way and two-way analysis of variance (ANOVA) for repeated measures; p values below 0.05 were considered significant. Figure 1 shows that treatment with DOC caused a progressive rise in MAP to an average of 122 ± 6 mm Hg (p<0.01) in the fourth week. The hypertension was associated with increases in cardiac output (p < 0.01) but no changes in heart rate and TPR. Analysis of the frequency distribution curves 3 for cardiac output between Days 3 and 28 of the study showed a sustained shift to the right on the control histograms in DOC-treated dogs. As shown in Table 1 , hypertension was accompanied by sustained declines in PRA and plasma irAng II, and a rise in plasma angiotensinogen. Concurrent effects of DOC included moderate hypokalemia and a tendency for plasma norepinephrine levels to decrease. These decreases were not statistically significant (p>0.05) by either one-way or two-way ANOVA, although the latter suggested an interaction between treatment and time. During the early stages of DOC hypertension we observed a transient fall in hematocrit (from 33 ± 1% to 31 ± 1% at Day 14), a rise in plasma sodium concentration, and an increase in plasma AVP levels. The composition of the cerebrospinal fluid of DOC-hypertensive dogs was altered with regard to angiotensinogen level on Days 14 and 28 and of cerebrospinal fluid AVP levels on Day 14. There was a tendency for an increase in cerebrospinal fluid sodium and no change in the concentration of cerebrospinal fluid irAng II. This latter finding is in contrast with the sustained fall in plasma Ang II (see Table 1 ). One month after initiation of DOC treatment, the COR was investigated under anesthesia. Compared with the data obtained in the same dogs during Week 4 of measurements, anesthesia did not mask the effects of DOC treatment on baseline values of MAP (101 ± 6 vs 120 ± 5 mm Hg), PRA (2.7 ± 0.6 vs 0.04 ± 0.03 ng/ml/hr), and plasma irAng II (8.3 ± 2.1 vs 0.1 ±0.3 pg/ml; sham vs DOC-treated). Although in both groups of dogs anesthesia produced equivalent rises in TPR (sham, + 93%; DOC-treated, + 90%), baseline values of cardiac output decreased 56% in DOC-treated dogs and 40% in the sham group (Figures 1 and 2 ). Thus the increased MAP of DOC-treated dogs was now primarily due to an increase in TPR. Statistically significant (p<0.05) rises in plasma and cerebrospinal fluid AVP levels were found only in the DOC-treated dogs to values averaging 6.7 ± 1.8 and 8.4 ± 1.3 pg/ml, respectively. Baseline right atrial pressure averaged 3.2 ± 0.9 mm Hg in the DOC-treated dogs compared with 2.3 ± 1.7 mm Hg in the sham group (p>0.05). Figure 2 shows that the COR was blunted in the chronic phase of DOC hypertension. In these dogs, the peak rises in MAP produced by carotid occlusion amounted to 40 ± 8 mm Hg versus 71 ± 11 mm Hg in the sham group (p<0.05). The characteristic increases in heart rate and cardiac output present in sham dogs were absent in DOC-treated animals. Section of the remaining vagus nerve caused further increases in the baseline values of MAP (10%) and TPR (14%) of only DOC-hypertensive dogs, while the associated increases in heart rate were comparable in magnitude in both groups. After vagotomy the peak increases in MAP produced by carotid occlusion averaged 74 ± 8 mm Hg (p>0.05) in DOC-treated dogs and 80 ± 15 mm Hg in sham animals. In addition, potentiation of the pressor response in the DOC group was associated with increases in cardiac output that were not present before vagotomy. Measurements of carotid sinus pressure during the occlusion period revealed comparable decreases in sham and DOC-treated dogs. In three other DOC-treated dogs (not included in Figure   ND = not detectable; CSF = cerebrospinal fluid.
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2) measurements of the peak changes in MAP produced by carotid occlusion before and after administration of atropine sulfate (0.13 mg/kg i.v.) were not statistically different (p>0.05).
Discussion
Sequential measurements of hemodynamics, plasma and cerebrospinal fluid hormones, and circulatory responses to stimulation of the COR described the pathophysiology of experimental hypertension produced solely by administration of DOC to dogs. The study provided three major findings: 1) a close relationship between increases in MAP and cardiac output, which may have been masked in other studies by the aggregate effects of salt feeding 8 -9 ; 2) evidence that brain Ang II participates in the evolution of DOC hypertension, as suggested by the persistent presence of the peptide in the cerebrospinal fluid when it was not detectable in the plasma; and 3) a depression in adrenergic function that may be related in part to enhanced inhibition of peripheral sympathetic drive by cardiac reflexes.
Beat-by-beat measurements of stroke volume and of cardiac output in trained, conscious dogs showed that the elevations in MAP correlated with increases in cardiac output, whereas TPR remained constant. Since heart rate did not change but hematocrit fell, the enhanced cardiac output is interpreted to be secondary NEUROHORMONAL MECHANISMS OF DOC-INDUCED HYPERTENSION/C/cno et al. to blood volume expansion, venoconstriction, or a combination of both. Volume expansion secondary to sodium retention has been shown in humans and in animal models of mineralocorticoid hypertension. 1 In previous studies, however, increases in cardiac output did not always accompany the elevations in pressure produced by steroids. '• l0 In dogs, hypertension due to metyrapone administration may be accompanied by increases in either cardiac output or TPR,' whereas both variables contribute to the hypertension produced by the combination of DOC and saline administration. 8 It is likely that the method used to monitor cardiac output influences results, since continual monitoring of stroke volume by chronically implanted flowmeters has greater accuracy than dye-dilution techniques. By graphic analysis of the distribution curves for cardiac output in each recording session, 3 we verified that the development of DOC hypertension in these dogs was regularly associated with increases in output. Previous studies suggested that the contribution of cardiac output and TPR to the rise in MAP may vary with the procedure used to produce hypertension, its severity, and its duration, and may even vary among animals. Thus, the current findings do not imply that increased cardiac output is a necessary mechanism for the emergence of DOC hypertension. The pitfalls of ascribing changes in arterial pressure to primary rises in either cardiac output or TPR are well documented." The observation that after anesthesia the elevated MAP of DOC-treated dogs was sustained by increased TPR underscores the idea that hemodynamic determinants of altered MAP are dependent on other factors, particularly humoral and neural mechanisms.
Our study also provides insight into the endocrine disturbances associated with DOC hypertension in conscious dogs. Correlative measurements of PRA and plasma irAng II confirmed that the hypertension is not dependent on increased activity of the peripheral renin-angiotensin system. 1 The increases in plasma angiotensinogen concentration suggest, however, that the suppression of plasma irAng II may be initially related to inhibition of renin secretion or production. The observation that the levels of cerebrospinal fluid angiotensinogen and irAng II are not suppressed during the early phase of hypertension suggests a role of brain Ang II in the evolution of this form of hypertension. This interpretation agrees with findings of increased reninlike activity and angiotensinogen concentration in the brain of DOC-salt-hypertensive rats 12 and our correlative studies of the relation between plasma and cerebrospinal fluid Ang II in the dog. 45 A contribution by the brain renin-angiotensin system to deoxycorticosterone acetate (DOCA)-salt hypertension in rats has been deduced based on the antihypertensive effects of central administration of captopril. 13 ' 14 In addition, there may be an interplay between brain Ang II and AVP in DOC-salt hypertension, since cerebroventricular administration of an angiotensin converting enzyme inhibitor was also associated with prevention of increases in plasma AVP levels. 14 Several studies point to AVP as being directly involved in the production of steroid hypertension. In rats with hereditary diabetes insipidus, DOCAsalt hypertension occurs only in animals given exogenous AVP. 13 In the present experiments, AVP levels were elevated in plasma at Day 7 and in the cerebrospinal fluid at Day 14 of DOC treatment. These findings are important indicators of an interaction among sodium, AVP, and Ang II in the genesis of this form of hypertension.
The contribution of the sympathetic nervous system to the causation of adrenocorticoid hypertension has not yet been established. Plasma norepinephrine levels decreased in hypertensive dogs given metyrapone 9 and in humans receiving mineralocorticoids. 1 In contrast, rats given DOC and salt supplements showed augmented plasma levels and an increased turnover of norepinephrine in the heart."' " Our data on the effects of DOC hypertension on plasma norepinephrine levels are not conclusive since the changes were not statistically significant. In both dogs and humans, an inverse relationship exists between sodium balance and plasma norepinephrine levels. 7 Since factors other than hypertension contribute to alterations in plasma norepinephrine levels, changes in blood catecholamines may not accurately reflect the participation of the sympathetic nervous system in the pathogenesis of DOC-hypertension. However, the failure of plasma norepinephrine levels to rise above baseline values in conjunction with diminished pressor responsiveness to stimulation of sympathetic reflexes in DOC-treated dogs suggests that adrenergic influences do not contribute directly to this type of hypertension.
Our protocol for the COR 67 causes circulatory adjustments during carotid occlusion to depend on the combined sensitivity of the baroreceptor input from the sole remaining carotid sinus and the cardiac afferents in the left vagus nerve. Compared with normal animals, DOC-hypertensive dogs showed impaired responses to carotid occlusion, consisting of a diminished reflex peak increase in MAP and an absence of any changes in either heart rate or cardiac output. The abnormal characteristics of the blunted COR in DOC-hypertensive dogs were corrected by removal of the vagal afferents, since this effect could not be duplicated by cholinergic blockade with atropine. Moreover, in DOC-hypertensive dogs only, cervical vagotomy produced significant additional increases in baseline MAP and TPR. After removal of the vagal afferents, the normalization of the pressor response to carotid occlusion was associated with restoration of the cardiac output component, a phenomenon that further implicates cardiac afferents in the control of cardiac performance."
Cardiopulmonary vagal afferents contribute to physiological control of the circulation by restraining adrenergic influences to the heart and the blood vessels." Our findings suggest that in DOC-hypertensive dogs, cardiopulmonary baroreceptors impose an abnormal inhibitory effect on the nervous control of blood pressure. It could be argued that the abnormal COR in these dogs may be related to baroreceptor resetting, cardiac and vascular wall restructuring, or increases in vascular reactivity; however, it is difficult to explain the rapid normalization of the COR by vagotomy based on these factors. Normalization of the reflex responsiveness suggests, instead, an alteration in the relative influence of arterial and cardiopulmonary baroreceptor reflexes in DOC hypertension. A change in the interaction between these baroreceptor reflexes in the regulation of lumbar and renal sympathetic nerve activity was shown in rabbits with renal hypertension" and in dogs exposed to either sodium depletion or loading. 7 In rats given DOCA-salt, 14 " impairment of baroreceptor reflex function is normalized by brain ventricular administration of an angiotensin converting enzyme inhibitor.
14 Although the mechanism underlying these effects has not been identified, it may result from increased cardiac afferent nerve activity, changes in the bulbospinal or forebrain integration of the influence of low-pressure and high-pressure baroreceptors on vasomotor neurons, or a combination of both.
In summary, DOC administration causes hypertension that is initially associated with hypernatremia, mild hypokalemia, and a transient elevation in plasma and cerebrospinal fluid AVP levels. The rises in MAP are accompanied by increases in both stroke volume and cardiac output, and suppression of blood, but not cerebrospinal fluid, levels of Ang II. Cardiovascular responses that depend primarily on a reflex augmentation of sympathetic function are blunted in DOC-hypertensive dogs before, but not after, removal of cardiopulmonary baroreceptor reflexes. These data are compatible with the possibility that the hypertensinogenic effects of DOC involve changes in central regulatory mechanisms that influence cardiovascular function and cardiopulmonary baroreceptor reflex control of sympathetic nerve activity.
